Performance of the GeneSoC Rapid PCR System in Detection of SARS-CoV-2 from Saliva Specimens

Ota, Kenji; Kurahara, Ryo; Tsukamoto, Chie; Kawamoto, Yasuhide; Akamatsu, Norihiko; Sasaki, Daisuke; Mitsumoto‐Kaseida, Fujiko; Sakamoto, Kei; Kosai, Kosuke; Hasegawa, Hiroo; Yamamoto, Kazuko; Izumikawa, Koichi; Mukae, Hiroshi; Yanagihara, Katsunori

doi:10.1128/spectrum.03259-22

Cited by 1 publication

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have reported detectable increases in saliva IgA after initial and/or booster vaccination with COVID-19 mRNA vaccines. 24,[26][27][28][29]46 Others, more consistent with our findings, have observed only minimal IgA responses in uninfected individuals. 25,30,31 A potential limitation of COVID-19 vaccine studies is possible inclusion of individuals with prior subclinical infections, as vaccination after prior SARS-CoV-2 infection can induce significant saliva anti-SCV2 spike IgA responses.…”

Section: Discussionsupporting

confidence: 92%

“…There is overall agreement in the literature that mRNA vaccination induces IgG responses in saliva. [24][25][26][27][28][29] However, reports on saliva IgA responses after COVID-19 mRNA vaccines have varied. Several studies have reported detectable increases in saliva IgA after initial and/or booster vaccination with COVID-19 mRNA vaccines.…”

Section: Discussionmentioning

confidence: 99%

“…Of those that have, most have found that COVID-19 mRNA vaccines induce spike-specific IgG antibodies in saliva. [24][25][26][27][28][29] In contrast, results regarding induction of saliva IgA by mRNA vaccines have been diverse, with some reporting measurable increases in saliva IgA after initial or booster vaccinations [24][25][26][27][28][29] and while other report minimal saliva IgA responses. 25,30,31 One particular challenge in addressing the knowledge gap of how well IM mRNA vaccines induce saliva antibodies is accounting for subclinical infections that may confound vaccine study results.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Subclinical SARS-CoV-2 Infections and Endemic Human Coronavirus Immunity Shape SARS-CoV-2 Saliva Antibody Responses

Conner,

Goguet,

Haines-Hull

et al. 2024

Preprint

View full text Add to dashboard Cite

This study characterized antibody responses induced by COVID-19 mRNA vaccination and SARS-CoV-2 infection in saliva. Utilizing multiplex microsphere-based immunoassays, we measured saliva anti-SARS-CoV-2 spike IgG, IgA, and secretory IgA in 1,224 saliva samples collected from healthcare workers in the Prospective Assessment of SARS-CoV-2 Seroconversion study between August of 2020 through December of 2022. By spring of 2022, most individuals had detectable spike-specific antibodies in saliva. Longitudinal measurements of saliva anti-SARS-CoV-2 nucleocapsid IgG revealed that most spike-specific IgA and secretory IgA detected in saliva was driven by subclinical and clinically-evident infections, rather than by vaccination alone. In contrast, saliva anti-SARS-CoV-2 spike IgG was strongly induced by vaccination and exhibited improved durability with hybrid immunity. Baseline levels of saliva antibodies to the endemic human coronaviruses positively correlated with post-vaccination anti-SARS-CoV-2 spike IgG levels. This study provides insights for development of vaccines that generate mucosal antibodies to respiratory pathogens.

show abstract